Patent intelligence · US
US 11090290
Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
Patent details — US 11090290
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 17, 2021
- Expiration
- Aug 12, 2041
- Applicant
- Monopar Therapeutics Inc.
- Claims
- 8
- CPC classes
- A61K, A61K2300/00, A61K31/4168, A61K45/06
Quick answer
US 11090290 (Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy) is held by Monopar Therapeutics Inc.. Status: granted. Granted Aug 17, 2021. Expires Aug 12, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Monopar Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K2300/00, A61K31/4168, A61K45/06, A61K9/006, A61K9/205
More from Monopar Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11090290?
US 11090290 (Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy) is held by Monopar Therapeutics Inc.. Status: granted. Granted Aug 17, 2021. Expires Aug 12, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11090290?
Monopar Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 11090290 expire?
Our index shows an expiration date of Aug 12, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.